In addition, abnormal BA metabolism activates cell survival-related signaling pathways such as phosphoinositide 3-kinase (PI3K)/AKT, which counteracts the pro-apoptotic effect of regorafenib and leads to HCC cells evading drug killing [54, 83]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.